Abstract The bisphosphonates ((HO) 2 P (O) CR 1 R 2 P (O)(OH) 2, BPs) were first shown to
inhibit bone resorption in the 1960s, but it was not until 30 years later that a detailed …

Patients with chronic kidney disease (CKD) are highly susceptible to cardiovascular (CV)
complications, thus suffering from clinical manifestations such as heart failure and stroke. CV …

Proximal tubule epithelial cells (PTEC) are susceptible to drug-induced kidney injury (DIKI).
Cell-based, two-dimensional (2D) in vitro PTEC models are often poor predictors of DIKI …

Introduction: Zoledronic acid (ZA) is a widely used bisphosphonate compound for the
prevention of skeletal metastasis-associated osteolysis and treatment of post-menopause …

Drug-induced proximal tubule (PT) injury remains a serious safety concern throughout drug
development. Traditional in vitro 2-dimensional (2D) and preclinical in vivo models often fail …

Zoledronic acid, a nitrogen‐containing bisphosphonate drug, is used for the treatment of
osteoporosis, Paget's disease of bone, and tumor‐induced osteolysis. Zoledronic acid has …

A bone imaging toolkit of 21 fluorescent probes with variable spectroscopic properties, bone
mineral binding affinities, and antiprenylation activities has been created, including a novel …

Zoledronate is a bisphosphonate that is widely used in the treatment of metabolic bone
diseases. However, zoledronate induces significant nephrotoxicity associated with acute …

Hydroxyapatite (HA) has been widely used as a bone substitute and more recently as a
carrier for local delivery of bone targeted drugs. Majority of the approved HA based …

To reply to as yet unmet medical needs to treat osteosarcoma, a form of primary bone
cancer, we conceived the 12b80 compound by covalently conjugating antineoplastic …